Core Insights - The company Yipinhong (300723) has received approval for three new drugs from the National Medical Products Administration, enhancing its product pipeline in the pediatric and chronic disease medication sectors [1][2] Drug Approvals - The three approved drugs include: - Esomeprazole magnesium enteric-coated suspension, indicated for gastroesophageal reflux disease and H. pylori eradication, with a projected sales scale of approximately 2.243 billion yuan in 2024 [1] - Ketoconazole sustained-release tablets, aimed at peripheral vascular diseases, with an expected sales scale of around 1.426 billion yuan in 2024 [1] - Compound polyethylene glycol (3350) electrolyte powder, for treating chronic constipation in children, with a projected sales scale of about 1.108 billion yuan in 2024 [2] Market Positioning - The approval of these drugs signifies the company's qualification to market these products domestically, thereby enriching its offerings in the pediatric and chronic disease medication fields and enhancing its competitive edge [2] Recent Developments - A week prior, the company announced the approval of a drug for treating mild to moderate Alzheimer's symptoms, with an expected sales scale of approximately 100 million yuan in 2024 [2] - The company is also advancing its innovative gout drug, AR882, which has completed the target enrollment of 680 patients in its domestic Phase III clinical trial [2][3] Clinical Trial Results - Data from completed global Phase II trials for AR882 indicate effective reduction of serum uric acid (sUA) and high rates of complete dissolution of gout stones in patients, providing a promising oral treatment option for chronic gout patients [3]

Group 1 - The core point of the article is that Yipinhong announced the approval of a drug registration certificate for its subsidiary, Guangzhou Lianrui Pharmaceutical Co., Ltd., regarding the sustained-release tablet of theobromine [2] Group 2 - The approval was granted by the National Medical Products Administration [2] - The announcement was made on the evening of November 28 [2]

格隆汇11月28日丨一品红(300723.SZ)公布，全资子公司广州市联瑞制药有限公司于近日收到国家药品 监督管理局核准签发的关于己酮可可碱缓释片的《药品注册证书》，根据核准的说明书，己酮可可碱缓 释片适应症为：周围性血管疾病，包括间歇性跛行和静息疼痛。己酮可可碱及其代谢产物通过降低血液 粘度来改善血液流变学特性,在慢性外周动脉疾病的患者中，可增加受影响微循环的血流，并提高组织 的氧合量。己酮可可碱确切的作用机制尚不明确。己酮可可碱可剂量依赖性地改善血液流变学，能降低 血液粘度和提高红细胞变形性。己酮可可碱能提高白细胞的变形能力和抑制嗜中性粒细胞的粘附和激 活。 ...

Core Viewpoint - The company has received approval from the National Medical Products Administration for the registration of its drug, Ketoconazole Sustained-Release Tablets, which is indicated for peripheral vascular diseases, including intermittent claudication and rest pain [1] Group 1 - The company's wholly-owned subsidiary, Guangzhou Lianrui Pharmaceutical Co., Ltd., has obtained the drug registration certificate for Ketoconazole Sustained-Release Tablets [1] - The approved indication for the drug includes treatment for peripheral vascular diseases [1]

格隆汇11月28日丨一品红(300723.SZ)公布，全资子公司广州市联瑞制药有限公司于近日收到国家药品 监督管理局核准签发的关于己酮可可碱缓释片的《药品注册证书》，根据核准的说明书，己酮可可碱缓 释片适应症为：周围性血管疾病，包括间歇性跛行和静息疼痛。己酮可可碱及其代谢产物通过降低血液 粘度来改善血液流变学特性,在慢性外周动脉疾病的患者中，可增加受影响微循环的血流，并提高组织 的氧合量。己酮可可碱确切的作用机制尚不明确。己酮可可碱可剂量依赖性地改善血液流变学，能降低 血液粘度和提高红细胞变形性。己酮可可碱能提高白细胞的变形能力和抑制嗜中性粒细胞的粘附和激 活。 ...

Core Viewpoint - The company has received approval from the National Medical Products Administration for the registration of its drug, Ketoconazole Sustained-Release Tablets, which is indicated for peripheral vascular diseases, including intermittent claudication and rest pain [1] Group 1 - The company's wholly-owned subsidiary, Guangzhou Lianrui Pharmaceutical Co., Ltd., has been granted the drug registration certificate [1] - The approved drug, Ketoconazole Sustained-Release Tablets, targets peripheral vascular diseases [1] - The specific indications for the drug include intermittent claudication and rest pain [1]

一品红公告称，公司全资子公司广州市联瑞制药有限公司收到国家药品监督管理局核准签发的己酮可可 碱缓释片《药品注册证书》。 ...